Ennogen, which focuses on European markets, will acquire the rights and intellectual property, while Aspen will retain a manufacturing and supply role under long-term agreements.
The collaboration will initially focus on biosimilar versions of Roche’s cancer treatment Polivy and Amgen’s thyroid eye disease therapy Tepezza.
NICRAT provides national leadership, institutional coordination and oversight, while BioVana is responsible for technical implementation.
Under the agreement, PureHealth will provide specialised dialysis services to community members who need financial or medical support to access treatment.
Trellis Health is adopting an artificial intelligence-centred approach from the outset, allowing it to build its digital infrastructure without the constraints of legacy systems.
The deal also gives Ferring access to early-stage cell therapies and research models targeting other women’s health needs.
Under the agreement, Astellas will pay up to US$285 million in upfront and potential future option exercise payments, alongside up to US$1.05 billion in development and commercial milestones.
The initiative builds on two years of collaboration following a memorandum of understanding signed by DoH and Novartis on 5 June 2024.
Under the partnership, Schneider Electric will provide PureHealth with access to its EcoStruxure Resource Advisor platform and establish a framework for developing sustainable infrastructure strategies across its facilities.
The proposed collaboration covers precision nutrition, longevity and healthy ageing, supportive oncology programmes, clinician education and research.